Ascletis Pharma Inc. (1672.HK)
Develops medicines to treat hepatitis C, HIV, and other viral and metabolic diseases in China
8.86-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-15.6%
The outlook
Ascletis Pharma trades at 8.86, well below both its 50- and 200-day moving averages and near the bottom of its 52-week range. Analyst coverage shows an average price target roughly 171% above the current level, though the overall sentiment leans bearish. The stock sits in a depressed technical position despite bullish longer-term analyst views.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range8% of the way from its 52-week low to high
Price targetAvg target +171% vs current price
Analyst price target
~12-month · 2 analysts23.99average target+170.8% vs now
Now 8.86
Low 16.01High 31.98
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$9.31B
52-wk high
19.86
52-wk low
7.95
50-day avg
11.12
200-day avg
13.46
Trailing P/E
—